# GHK-Cu: Research Overview — Agility Peptide > A literature summary of GHK-Cu (copper tripeptide-1), studied for skin regeneration, matrix repair and collagen synthesis. Covers gene-expression evidence, human topical trials and the skin-permeability problem. The broadest human evidence of the four compounds on this desk — most of it topical, and limited by a well-characterized skin-permeability barrier the field is still solving. ## The short version GHK-Cu is a three-amino-acid peptide — glycine, histidine, lysine — chelated to a single copper ion. You will also see it labeled copper tripeptide-1. The same GHK sequence occurs naturally inside type I collagen, the main structural protein of skin and tendon, which is a direct clue to its function: it signals skin and connective-tissue cells to rebuild their scaffolding of collagen and elastin [16]. Of the four compounds on this desk, GHK-Cu has the most human evidence — but that evidence is mostly *topical*, meaning applied to the skin surface, and it runs into a built-in ceiling: the peptide does not cross intact skin well on its own (skin permeability coefficient ~2.43 x 10^-4 cm/h) [17][13]. Topical copper-peptide cosmetics are legal and widely sold; injectable or whole-body use is unapproved and research-only [13]. This page summarizes the studies and recommends no dose or regimen. ## What it is GHK-Cu is the linear tripeptide glycyl-L-histidyl-L-lysine *chelated* (bound in a stable coordinate claw) one-to-one to a copper(II) ion. Copper is coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and a backbone amide nitrogen, leaving the lysine side chain free. It carries a small net positive charge (molecular formula C14H23CuN6O4+). The bare GHK tripeptide sequence appears endogenously within the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin — so the body already uses this motif. Copper coordination is required for most of the reported bioactivities, so GHK (the free tripeptide) and GHK-Cu (the copper chelate) are not interchangeable, despite being frequently conflated in secondary literature [16]. ## How it works GHK-Cu operates on two levels simultaneously: as a *copper chaperone* delivering Cu(II) where it is needed for enzymatic activity, and as a broad signaling molecule. At picomolar-to-nanomolar concentrations it stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the matrix metalloproteinases (enzymes that break down matrix) against their TIMP inhibitors [16]. The copper ion itself enables lysyl-oxidase-mediated cross-linking that stitches collagen and elastin fibers together, plus a superoxide-dismutase-like antioxidant role. At the gene level, a Connectivity Map analysis reported that GHK shifts expression of approximately 31.2% of human genes at a 50%-or-greater change threshold — roughly 59% upregulated, 41% downregulated — strongly stimulating the ubiquitin-proteasome (protein quality-control) system and DNA-repair and antioxidant gene sets [14]. One honest correction: the widely repeated "~4,000 genes" figure is an extrapolation; the verified 50%-threshold table accounts for roughly 2,100 genes [14]. ## What the research shows *Skin regeneration.* The canonical 2015 review documents GHK-Cu stimulating collagen, dermatan sulfate, chondroitin sulfate and decorin synthesis, notes that plasma GHK concentration falls from about 200 ng/mL at age 20 to about 80 ng/mL by age 60, and reports topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in the same comparison [16]. *Gene expression.* The 2018 Connectivity Map analysis quantified a broad transcriptomic shift toward tissue-repair, protein-quality-control, DNA-fidelity and antioxidant programs [14]. *A controlled human signal.* In a 6-month trial of 45 men with androgenetic alopecia, a complex of 5-aminolevulinic acid plus glycyl-histidyl-lysine peptide increased hair count by 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) versus 9.6 for placebo (p<0.05), with no adverse events in any group — the strongest controlled human efficacy signal for a GHK-containing topical, though it used a combination product rather than pure GHK-Cu [15]. *Delivery quantified.* A 2025 review confirms poor stratum-corneum permeability (clogP -2.24) as the central barrier, and evaluates palmitoylation (raising clogP to 1.14) and microneedle pretreatment (~134 nmol GHK permeated with microneedling vs. none through intact skin) as enhancement strategies [13]. A skin-penetration study quantified copper delivery from GHK-Cu through ex vivo human dermatomed skin: permeability coefficient 2.43 ± 0.51 x 10^-4 cm/h, with 136.2 ± 17.5 µg/cm² permeated and 97 ± 6.6 µg/cm² retained as a dermal depot over 48 hours [17]. ## Reported effects, cautions & safety Topical copper-peptide products carry a long real-world safety record, but several cautions are documented in the literature: - *No approved drug indication.* There is no FDA- or EMA-approved GHK-Cu therapeutic product by any route. Topical copper tripeptide-1 is a legal cosmetic ingredient; injectable or systemic use is unapproved research-only [13]. - *Thin evidence beyond skin.* Human clinical data are limited to small topical dermatology trials and a single 45-patient combination hair-loss RCT. No validated human PK data (half-life, Cmax, bioavailability) exists for injectable or systemic GHK-Cu; community dosing protocols have no peer-reviewed basis [15]. - *Localized hyperpigmentation.* Reported in some topical copper-peptide applications — for example around 40% in one acne-scar microneedling study — a real user-risk [13]. - *Formulation incompatibility.* Vitamin C / ascorbic acid and low-pH acids can degrade both actives through copper-mediated redox chemistry — a known user-error risk. - *Theoretical copper accumulation.* Prolonged systemic use raises a theoretical copper-balance concern, though no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record. - *Single-investigator origin.* A large share of foundational mechanistic and review literature originates from one investigator and colleagues, limiting independent replication of the broader gene-expression and anti-aging claims [14]. No community-anecdote reports are compiled in this desk's source material for GHK-Cu as a standalone compound; the cautions above come from the cited literature. ## Where it fits in recovery research GHK-Cu is the matrix-and-scaffolding specialist on this desk, and the compound with the strongest human evidence — but that evidence is anchored to the skin surface, where its own permeability problem limits how far it reaches [13]. Where [BPC-157](/bpc-157) and [TB-500](/tb-500) live almost entirely in animal models, GHK-Cu has decades of topical cosmetic use and small-scale controlled trials; what it lacks is validated systemic human pharmacokinetics. It completes the desk's repair picture with the collagen-rebuild angle. It also appears as the mass-dominant component in the [KLOW](/klow) blend. Compare all four on the [comparison page](/compare). ![GHK-Cu research illustration](/images/ghk-cu.webp) --- Peer-reviewed data, plain-English summaries — a research digest, not a dose guide and not a product for sale.